您的购物车当前为空
DLK-IN-1 is a selective oral active inhibitor of bisleucine zipper kinase (DLK, MAP3K12) with Ki of 3 nM. DLK-IN-1 is active in the Alzheimer's disease model, retains excellent CNS permeability, and after multiple days of administration, its concentration exceeds the concentration required for DLK inhibition in the brain, so it has good tolerance Acceptability.
DLK-IN-1 is a selective oral active inhibitor of bisleucine zipper kinase (DLK, MAP3K12) with Ki of 3 nM. DLK-IN-1 is active in the Alzheimer's disease model, retains excellent CNS permeability, and after multiple days of administration, its concentration exceeds the concentration required for DLK inhibition in the brain, so it has good tolerance Acceptability.

| 规格 | 价格 | 库存 | 数量 |
|---|---|---|---|
| 2 mg | ¥ 3,630 | 5日内发货 | |
| 5 mg | ¥ 4,570 | 5日内发货 | |
| 25 mg | ¥ 17,600 | 10-14周 | |
| 50 mg | ¥ 22,900 | 10-14周 | |
| 100 mg | ¥ 31,500 | 10-14周 | |
| 1 mL x 10 mM (in DMSO) | ¥ 4,930 | 5日内发货 |
TargetMol的所有产品仅用作科学研究或药证申报,不能被用于人体,我们不向个人提供产品和服务。请您遵守承诺用途,不得违反法律法规规定用于任何其他用途。
凭借在化合物合成方面的丰富经验,我们可以根据您的研究需求为该产品提供快速定制合成服务。
| 产品描述 | DLK-IN-1 is a selective oral active inhibitor of bisleucine zipper kinase (DLK, MAP3K12) with Ki of 3 nM. DLK-IN-1 is active in the Alzheimer's disease model, retains excellent CNS permeability, and after multiple days of administration, its concentration exceeds the concentration required for DLK inhibition in the brain, so it has good tolerance Acceptability. |
| 靶点活性 | DLK:ki:3 nM |
| 分子量 | 423.43 |
| 分子式 | C20H24F3N5O2 |
| CAS No. | 1620574-24-4 |
| Smiles | [H][C@@]12CN(C[C@]1([H])[C@H]2c1cc(nn1C(C)C)-c1cnc(N)c(OC(F)(F)F)c1)C1COC1 |
| 密度 | 1.59 g/cm3 (Predicted) |
| 存储 | Powder: -20°C for 3 years | In solvent: -80°C for 1 year Shipping with blue ice/Shipping at ambient temperature. 实际储存温度请以COA为准 | |||||||||||||||||||||||||||||||||||
| 溶解度信息 | DMSO: 62.5 mg/mL (147.6 mM), Sonication is recommended. | |||||||||||||||||||||||||||||||||||
溶液配制表 | ||||||||||||||||||||||||||||||||||||
DMSO
该溶液配制表仅适用于固体产品。对于液体产品,请根据标明的浓度或密度计算稀释方案。 | ||||||||||||||||||||||||||||||||||||
对于不同动物的给药剂量换算,您也可以参考 更多